Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries

Ernest Choy, Roberto Caporali, Ricardo Xavier, Bruno Fautrel, Raimón Sanmarti, Min Bao, Corrado Bernasconi, Attila Pethö-Schramm, Ernest Choy, Roberto Caporali, Ricardo Xavier, Bruno Fautrel, Raimón Sanmarti, Min Bao, Corrado Bernasconi, Attila Pethö-Schramm

Abstract

Objectives: The aim of this pooled analysis of the TOZURA study programme was to evaluate the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) in patients with moderate to severe RA who had an inadequate response to csDMARD or anti-TNF agent therapy or who were MTX naïve.

Methods: TOZURA is a multinational, open-label, single-arm, common-framework, phase 4 study programme (11 protocols, 22 countries). Patients received TCZ-SC 162 mg each week for ⩾24 weeks, administered at the investigator's discretion, as monotherapy or in combination with a csDMARD. Efficacy, safety and immunogenicity were evaluated; propensity score-based matching was used for between-group comparisons.

Results: Of 1804 patients, 353 (19.6%) received monotherapy and 1451 (80.4%) received combination therapy. The 28-joint DAS using ESR (DAS28-ESR) in both groups decreased significantly from baseline to week 24 (mean change: monotherapy -3.40, combination therapy -3.46), with no significant difference between groups (P = 0.46). The proportion of patients who achieved DAS28-ESR or Clinical Disease Activity Index remission or ACR 20/50/70/90 responses was similar between groups. Overall, 13.9% of patients withdrew-6.2% for safety reasons and 1.6% for insufficient therapeutic response; 5.8% of patients experienced one or more serious adverse events [14.6/100 patient-years (PY)]; six deaths occurred (0.64/100 PY).

Conclusion: In a common framework of 11 studies in 22 countries, this phase 4 study programme confirmed TCZ-SC's known efficacy and safety profile with comparable effects as monotherapy and in combination with csDMARDs.

Trial registration: ClinicalTrials.gov (http://www.clinicaltrials.gov) NCT01941940, NCT01941095, NCT01951170, NCT01987479, NCT01988012, NCT01995201, NCT02001987, NCT02011334, NCT02031471, NCT02046603 and NCT02046616.

© The Author 2017. Published by Oxford University Press on behalf of Kazusa DNA Research Institute.

Figures

F ig . 1
Fig. 1
Patient disposition at baselinecsDMARD: conventional synthetic disease-modifying anti-rheumatic drug; qw: once weekly; TCZ-SC: subcutaneous tocilizumab.
F ig . 2
Fig. 2
DAS28-ESR and CDAI disease activity at week 24 No imputation of data was used. CDAI: Clinical Disease Activity Index; csDMARD: conventional synthetic disease-modifying anti-rheumatic drug; DAS28-ESR: Disease Activity Score in 28 joints using erythrocyte sedimentation rate; TCZ-SC: subcutaneous tocilizumab.
F ig . 3
Fig. 3
Mean (A) DAS28-ESR, (B) CDAI score and (C) HAQ-DI score over 24 weeks *P < 0.0001 for TCZ-SC monotherapy comparing week 1 with week 24. **P < 0.0001 for TCZ-SC + csDMARD comparing week 1 with week 24. BL: baseline; CDAI: Clinical Disease Activity Index; csDMARD: conventional synthetic disease-modifying anti-rheumatic drug; DAS28-ESR: Disease Activity Score in 28 joints using erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; TCZ-SC: subcutaneous tocilizumab.
F ig . 4
Fig. 4
ACR and EULAR responses at week 24 No imputation of data was used. ACR: American College of Rheumatology; csDMARD: conventional synthetic disease-modifying anti-rheumatic drug; EULAR: European League Against Rheumatism; TCZ-SC: subcutaneous tocilizumab.

References

    1. Eulenfeld R, Dittrich A, Khouri C. et al. Interleukin-6 signalling: more than Jaks and STATs. Eur J Cell Biol 2012;91:486–95.
    1. Smolen JS, Beaulieu A, Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.
    1. Genovese MC, McKay JD, Nasonov EL. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80.
    1. Emery P, Keystone E, Tony HP. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.
    1. Jones G, Sebba A, Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88–96.
    1. Kremer JM, Blanco R, Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609–21.
    1. Burmester GR, Rubbert-Roth A, Cantagrel A. et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69–74.
    1. Kivitz A, Olech E, Borofsky M. et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 2014;66:1653–61.
    1. Ogata A, Tanimura K, Sugimoto T. et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 2014;66:344–54.
    1. Burmester GR, Rubbert-Roth A, Cantagrel A. et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 2016;75:68–74.
    1. Kivitz A, Olech E, Borofsky MA. et al. The efficacy and safety of tocilizumab subcutaneous Q2W and following escalation from Q2W to QW therapy in combination with traditional DMARDs in patients with moderate to severe rheumatoid arthritis at 96 weeks. Arthritis Rheumatol 2014;66:S1076–7.
    1. Ogata A, Amano K, Dobashi H. et al. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study. J Rheumatol 2015;42:799–809.
    1. Kivitz A, Wallace T, Olech E. et al. Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study. Rheumatol Ther 2016;3:291–304.
    1. Stubenrauch K, Wessels U, Birnboeck H. et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597–609.
    1. Dougados M, Kissel K, Sheeran T. et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43–50.
    1. Burmester GR, Rigby WF, van Vollenhoven RF. et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 2016;75:1081–91.
    1. Bykerk VP, Ostor AJ, Alvaro-Gracia J. et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol 2015;34:563–71.
    1. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011;100:354–87.
    1. Burmester GR, Choy E, Kivitz A. et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis 2017;76:1078–85.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe